On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
-
BUSINESS AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
-
BUSINESS Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
-
REGULATORY Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
-
BUSINESS Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
April 11, 2025
-
REGULATORY Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
-
REGULATORY Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
-
REGULATORY Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
-
ORGANIZATION No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
-
REGULATORY Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
-
REGULATORY Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
April 7, 2025
-
BUSINESS Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll
April 4, 2025
-
REGULATORY Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
April 3, 2025
-
REGULATORY Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
-
ORGANIZATION JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
April 2, 2025
-
COMMENTARY How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
-
REGULATORY Japan Jittery over Mass Layoffs at FDA, though HHS Says Reviewers Won’t Be Affected
March 31, 2025
-
REGULATORY Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
March 28, 2025
-
BUSINESS Kyushu University Offshoot Eyes US Nod for Repositioned ROP Drug Candidate
March 27, 2025
-
BUSINESS J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…